



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Cancer Drug Manual** – New: Daratumumab Revised: Afatinib, Bortezomib, Lenvatinib, Trametinib; Acknowledgment of Editorial Board and Contributors
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts**: Revised: BRAJACTT, BRAJACTTG, BRAJDCARBT, BRAJFECDT, BRAJTDC, BRAJTR, UGOOVBEVLD, GOOVCYCPO, GOOVDOC, GOOVETO, GOOVLDOX, GOOVPLDC, GOOVTAX3, GOOVVIN, GOTDEMACO, KSLDO, ULYIDELAR
- **Website Resources and Contact Information**

CANCER DRUG MANUAL

NEW MONOGRAPHS AND PATIENT HANDOUTS

The following drug is currently not funded by BC Cancer. The monograph and handout are being made available for reference only:

The **Daratumumab Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Kevin Song (hematologist) and Linda Hamata (pharmacist) from the BC Cancer Lymphoma Tumour Group. Daratumumab is a human IgG1 kappa anti-CD38 monoclonal antibody that binds to the transmembrane glycoprotein CD38 to potently inhibit the growth of CD38 expressing tumour cells. Infusion-related reactions are common, especially with the first infusion and include respiratory symptoms (e.g., nasal congestion, cough, and throat irritation), chills, nausea, and vomiting. Severe reactions have also been reported, including bronchospasm, edema, hypertension, and dyspnea. Slow initial infusion rates, pre-infusion steroids, antihistamines, antipyretics, and post-infusion steroids are used to reduce the incidence of infusion-related reactions. Other serious side effects include neutropenia, thrombocytopenia, anemia, and infections.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

- **Afatinib Monograph and Patient Handout**: *Supply and Storage*: clarified packaging and storage conditions
- **Bortezomib Monograph and Chemotherapy and Preparation Chart**: *Solution Preparation and Compatibility*: revised preparation information for SC administration
- **Lenvatinib Monograph and Patient Handout**: *Supply and Storage*: clarified packaging and storage conditions
- **Trametinib Monograph and Patient Handout**: *Supply and Storage*: clarified packaging and storage conditions

CANCER DRUG MANUAL

ACKNOWLEDGMENT OF CDM CONTRIBUTORS

The Cancer Drug Manual staff would like to acknowledge the contributions of the Editorial Board and the expert reviewers for their ongoing support of the Manual, and for generously sharing their time and expertise throughout the year.

Editorial Board	Expert Reviewers
<p><u>Physicians:</u> Angela Chan (Medical Oncologist, BC Cancer) Dave Fenton (Medical Oncologist, BC Cancer) Deepa Wadhwa (Medical Oncologist, BC Cancer) Jeff Davis (Pediatric Oncologist, BC Children’s Hospital)</p> <p><u>Nurses:</u> Terri Gray (BCCA-CN) Karen Janes (BCCA-VC)</p> <p><u>Pharmacists:</u> Sanna Pellatt (BCCA-VIC) Mandeep Bains (BCCA-VC) Roberta Esau (BC Children’s Hospital) Clarissa Cheng (Burnaby Hospital)</p>	<p><u>Physicians:</u> Janine Davies (Medical Oncologist, BC Cancer) Jeff Davis (Pediatric Oncologist, BC Children’s Hospital) Alina Gerrie (Medical Oncologist, BC Cancer) Cheryl Ho (Medical Oncologist, BC Cancer) Vincent Ho (Medical Oncologist, BC Cancer) Chris Lee (Medical Oncologist, BC Cancer) Yasser Abou Mourad (Hematologist, Leukemia/BMT Program of BC) Sunil Parimi (Medical Oncologist, BC Cancer) Sanjay Rao (Medical Oncologist, BC Cancer) Kerry Savage (Medical Oncologist, BC Cancer) Kevin Song (Hematologist, Leukemia/BMT Program of BC) Sophie Sun (Medical Oncologist, BC Cancer) Heather Sutherland (Hematologist, Leukemia/BMT Program of BC) Anna Tinker (Medical Oncologist, BC Cancer)</p> <p><u>Pharmacists:</u> Alysha Bharmal (BCCA-FVC) Jackie Buston (BCCA-VIC) Linda Calwill (BCCA-AC) James Conklin (BCCA-VC) Roberta Esau (BC Children’s Hospital) Linda Hamata, (BCCA-VC) Katherine Lacaria (Vancouver General Hospital) Karen Mason (BCCA-FVC) Khushminder Rai (BCCA-AC) Robert Tillmanns (BCCA-AC)</p>

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACTT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN)

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACTTG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN)
BRAJDCARBT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using docetaxel, carboplatin, and trastuzumab (HERCEPTIN)
BRAJFECDT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN)
BRAJTDC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN), docetaxel and cyclophosphamide
BRAJTR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, LVEF cut-off, institutional name and logo updated</i>	Adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN) following the completion of chemotherapy (sequential)
UGOOVBEVLD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Treatment of platinum resistant epithelial ovarian cancer with bevacizumab and doxorubicin pegylated liposomal (CAELYX)
GOOVCYCPO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using using metronomic low-dose oral cyclophosphamide
GOOVDOC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using docetaxel
GOOVETO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using etoposide
GOOVLDOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Drug name clarified, institutional name and logo updated</i>	Treatment of epithelial ovarian cancer relapsing after primary treatment using doxorubicin pegylated liposomal (CAELYX)
GOOVPLDC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Drug name clarified, institutional name and logo updated</i>	Treatment of epithelial ovarian cancer relapsing after primary treatment using doxorubicin pegylated liposomal (CAELYX) and carboplatin
GOOVTAX3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using paclitaxel
GOOVVIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name updated</i>	Treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using vinorelbine
GOTDEMACO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy for high risk gestational trophoblastic neoplasia using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine
KSLDO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Drug name clarified, institutional name and logo updated</i>	Therapy of Kaposi's sarcoma using doxorubicin pegylated liposomal (CAELYX)
ULYIDELAR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Standard order information added</i>	Treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 672247		bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			
Oncology Drug Information	604-877-6275		bulletin@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		druginfo@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		nursinged@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		requests@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		mclin@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	ilundie@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	oscar@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		cap_bcca@bccancer.bc.ca
BC Cancer-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		rxchemocert@bccancer.bc.ca
BC Cancer-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Mario de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 James Conklin, BSc(Pharm), ACPR
 Jagbir Kaur, RN, MN

Lorraine Leitz, MLS
 Caroline Lohrisch, MD
 Alison Pow, BSc(Pharm)